Intracerebral Hemorrhage: Advances in Preclinical Studies 2.0

Dear Colleagues,

Intracerebral hemorrhage (ICH) is a major public health problem and severe subtype of stroke characterized by cerebral bleeding. In comparison to other stroke subtypes, ICH is associated with the highest mortality and morbidity rates. Additionally, the incidence of ICH is expected to increase due to aging and the increasing use of anticoagulants. To date, there is no effective treatment for ICH, making it the deadliest subtype of stroke.

ICH results in severe brain injury, which is categorized into primary and secondary brain damage. The primary brain damage is mainly attributed to the mass effect of the hematoma, whereas the mechanisms of the secondary brain damage include, but are not limited to, neuroinflammation, oxidative stress, apoptosis, and excitotoxicity. The secondary brain injury, which persists for a longer period, contributes to long-term neurological deficits and is considered a viable target for therapeutic intervention. However, given the complex pathophysiology of ICH, further elucidation of the brain injury mechanisms is imperative for the identification of novel molecular targets for therapeutic intervention.

Herein, we attempt to provide an update on ICH by inviting reviews, research articles, and short communications for the Special Issue entitled “Intracerebral Hemorrhage: Advances in Preclinical Studies”.

We look forward to your contributions.

Dr. Sangeetha Sukumari-Ramesh
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• neuroinflammation
• oxidative stress
• neurodegeneration
• neurological deficits
• blood–brain barrier damage

• Intracerebral Hemorrhage: Advances in Preclinical Studies in Biomolecules (6 articles)